Rebecca Byam

CIK: 0001866256

Transaction Breakdown

Open Market Buys (P)3 (100.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

HCWB

HCW Biologics Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

HCWB
HCW Biologics Inc.
May 22, 2026
Purchase(P)
Direct
14.2K shares at avg. $1.41$20K
HCWB
HCW Biologics Inc.
May 8, 2025
Purchase(P)
Direct
8.5K shares at avg. $26.00$220K
HCWB
HCW Biologics Inc.
May 7, 2025
Purchase(P)
Common Stock Purchase Warrant
Direct
4.2K shares-

		Type	Shares	Price		Ownership
May 22, 2026	HCWB HCW Biologics Inc.	Purchase(P)	14,235	$1.41	$20,000	Direct
May 8, 2025	HCWB HCW Biologics Inc.	Purchase(P)	8,462	$26.00	$220,012	Direct
May 7, 2025	HCWB HCW Biologics Inc.	Purchase(P) Common Stock Purchase Warrant	4,231	-	-	Direct

1-3 of 3 transactions

About Byam Rebecca

Byam Rebecca (SEC CIK 0001866256) files insider reports with the SEC as Chief Financial Officer of HCW Biologics Inc. (HCWB).

Signal8 holds 2 ownership filings by Byam Rebecca, all Form 4s, filed between May 9, 2025 and May 27, 2026. Those filings report 3 transactions, from May 7, 2025 to May 22, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Byam Rebecca's filings is in MIRAMAR, FL.

Recent filings by Byam Rebecca

May 22, 2026: Open-market purchase of HCWB shares (Form 4, code P).
May 8, 2025: Open-market purchase of HCWB shares (Form 4, code P).
May 7, 2025: Open-market purchase of HCWB derivative securities (Form 4, code P).

Other insiders filing for HCW Biologics Inc. (HCWB)

Wong Hing C, Chief Executive Officer
GARRETT SCOTT T, Director
Winer Gary M, Director
Flowers Lee, SVP of Business Development
Greene Rick S., Director

How to read Form 4 transaction codes